A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

Inclusion Criteria:

• Maintenance Period- Participants who achieved clinical response and/or clinicalremission at week 14 of TV48574-IMM-20036 (the 14-week DRF study) or in there-induction period of this study.

• Re-induction- Participants who did not achieve clinical response and/or clinicalremission at week 14 of the TV48574-IMM-20036 DRF study

NOTE- Additional criteria may apply, please contact the investigator for more information

Exclusion Criteria:

• Participants who discontinued the TV48574-IMM-20036 study before scheduled week 14visit (any reason including lack of efficacy, safety, or personal reasons)

• Participant has any concomitant conditions or treatments that could interfere withstudy conduct, influence the interpretation of study observations/results, or putthe participant at increased risk during the study as judged by the investigatorand/or the clinical study physician.

• Participant anticipates requiring major surgery during this study.

• Participant is currently pregnant or lactating or is planning to become pregnant orto lactate during the study or for at least 50 days after administration of the lastdose of IMP in case of early termination. Any woman becoming pregnant during thestudy will be withdrawn from the study.

NOTE- Additional criteria apply, please contact the investigator for more information